Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Archives of General Psychiatry

• Publication date

  1997-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1001/ARCHPSYC.1997.01830220085012PMID 9337777
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Applications of Magnetic Resonance Spectroscopy

  1997cited by this paper
• An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients.

  1996cited by this paper
• Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17.

  1995cited by this paper
• Regional Brain Activity in Chronic Schizophrenic Patients during the Performance of a Verbal Fluency Task

  1995cited by this paper
• Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features.

  1995cited by this paper
• Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis.

  1995cited by this paper
• Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.

  1995cited by this paper
• Glutamate receptor dysfunction and schizophrenia.

  1995cited by this paper
• Hypofrontality revisited: a high resolution single photon emission computed tomography study in schizophrenia.

  1995cited by this paper
• Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia

  1995cited by this paper
• The use of a priori knowledge to quantify short echo in vivo 1h mr spectra

  1995cited by this paper
• A functional neuroanatomy of hallucinations in schizophrenia

  1995cited by this paper
• An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy.

  1995cited by this paper
• Clinical applications of magnetic resonance spectroscopy.

  1994cited by this paper
• Time and frequency domain analysis of NMR data compared: An application to 1D 1H spectra of lipoproteins

  1994cited by this paper
• Matching the limits of clinical inference to the limits of quantitative methods: A formal appeal to practice what we consistently preach.

  1994cited by this paper
• 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates.

  1994cited by this paper
• Analysis of macromolecule resonances in 1H NMR spectra of human brain

  1994cited by this paper
• Estimation of metabolite concentrations from localized in vivo proton NMR spectra

  1993cited by this paper
• Single-photon emission computed tomography with 99mTc-exametazime in unmedicated schizophrenic patients.

  1993cited by this paper
• Single-photon emission computed tomography with 99mTc-exametazime in unmediated schizophrenic patients

  1993cited by this paper
• Relationship of Cingulate Cortex to Schizophrenia and Other Psychiatric Disorders

  1993cited by this paper
• Structural Organization of Cingulate Cortex: Areas, Neurons, and Somatodendritic Transmitter Receptors

  1993cited by this paper
• SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test.

  1993cited by this paper
• Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types

  1993cited by this paper
• In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard.

  1993cited by this paper
• Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra.

  1993cited by this paper
• Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.

  1993cited by this paper
• Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London.

  1992cited by this paper
• Cerebral MRS in infant with suspected Reye's syndrome.

  1992cited by this paper
• Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy.

  1992cited by this paper
• Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain.

  1992cited by this paper
• Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat.

  1992cited by this paper
• Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.

  1992cited by this paper
• Patterns of Cerebral Blood Flow in Schizophrenia

  1992cited by this paper
• Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients.

  1991cited by this paper
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline

  1991cited by this paper
• Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; Myo‐inositol and related metabolites

  1991cited by this paper
• Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy.

  1991cited by this paper
• Metabolism and role of glutamate in mammalian brain.

  1990cited by this paper
• In vivo proton spectroscopy in presence of eddy currents

  1990cited by this paper
• Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions.

  1990cited by this paper
• Improvements in localized proton NMR spectroscopy of human brain. Water suppression, short echo times, and 1 ml resolution

  1990cited by this paper
• Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268

  1990cited by this paper
• Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia

  1989cited by this paper
• Localized proton spectroscopy using stimulated echoes.

  1987cited by this paper
• Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

  1986cited by this paper
• Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia.

  1983cited by this paper
• Glutamate as a CNS transmitter. I. Evaluation of glucose and glutamine as precursors for the synthesis of preferentially released glutamate.

  1979cited by this paper
• GLUTAMINE—A MAJOR SUBSTRATE FOR NERVE ENDINGS

  1978cited by this paper
• Measuring handedness with questionnaires.

  1977cited by this paper
• An Algorithm for Least-Squares Estimation of Nonlinear Parameters

  1963cited by this paper
• Analysis of covariance: Its nature and uses.

  1957cited by this paper

• Elevated glutamine but not glutamate is associated with clozapine eligibility in an early psychosis sample

  2026cites this paper
• Concerted elevations of cortical and striatal glutamate and GABA in antipsychotic-free individuals at clinical high-risk for psychosis

  2025cites this paper
• Hippocampal subfield activity in schizophrenia: Effects of the disease course.

  2025cites this paper
• Aging in Schizophrenia: Perspectives on Molecular Mechanisms and a Mini-review.

  2025cites this paper
• Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials.

  2025cites this paper
• Schizophrenia and antipsychotic medications present distinct and shared gut microbial composition: A meta-analysis.

  2024cites this paper
• Longitudinal Analysis of Brain Function-Structure Dependencies in 22q11.2DS and Psychotic Symptoms.

  2024cites this paper
• Meta-analytic evidence of elevated choline, reduced N-acetylaspartate, and normal creatine in schizophrenia and their moderation by measurement quality, echo time, and medication status

  2023cites this paper
• Assessing the effects of antipsychotic medications on schizophrenia functional analysis: a postmortem proteome study

  2022cites this paper
• Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users

  2022cites this paper
• Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies

  2021cites this paper
• Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level

  2021cites this paper
• Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia

  2021cites this paper
• Medial Prefrontal Cortex Glutamate is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of 1H-MRS Studies

  2021cites this paper
• Schizophrenia-Like Behavioral Impairments in Mice with Suppressed Expression of Piccolo in the Medial Prefrontal Cortex

  2021cites this paper
• Psychiatric phenotypes associated with hyperprolinemia: A systematic review

  2021cites this paper
• Cannabidiol modulation of hippocampal glutamate in early psychosis

  2021cites this paper
• Alterations of neurometabolism in the dorsolateral prefrontal cortex and thalamus in transition to psychosis patients change under treatment as usual - A two years follow-up 1H/31P-MR-spectroscopy study.

  2021cites this paper
• Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients

  2020cites this paper
• Insular Cell Integrity Markers Linked to Weight Concern in Anorexia Nervosa—An MR-Spectroscopy Study

  2020cites this paper
• Magnetic resonance spectroscopy studies in subjects with high risk for psychosis: A meta-analysis and review.

  2020cites this paper
• Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis

  2020cites this paper
• Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study

  2020cites this paper
• ALDH4A1 expression levels are elevated in postmortem brains of patients with schizophrenia and are associated with genetic variants in enzymes related to proline metabolism.

  2020cites this paper
• Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study.

  2019influential citation
• The neurocognitive and neurochemical effects of cannabidiol in psychosis

  2019cites this paper
• Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis

  2019cites this paper
• Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study

  2019influential citation
• EC PSYCHOLOGY AND PSYCHIATRY Thesis The Birth of Schizophrenia in the Family: When Conflicting Messages Hurt

  2019cites this paper
• Mitochondrial Function and Inflammation in Individuals at Clinical High Risk for Psychosis and Patients with Early Stage Schizophrenia

  2019cites this paper
• Investigating the effects of repeat ketamine exposure : linking brain structural imaging changes to cellular alterations

  2019cites this paper
• Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.

  2019cites this paper
• Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial

  2018cites this paper
• Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a 1[H]-spectroscopy twin study

  2018cites this paper
• Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia

  2018cites this paper
• Neurometabolite levels in antipsychotic‐naïve/free patients with schizophrenia: A systematic review and meta‐analysis of 1H‐MRS studies

  2018cites this paper
• Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.

  2018cites this paper
• Comparative Studies of Glutamine Synthetase Levels in the Brains of Patients with Schizophrenia and Mentally Healthy People

  2018cites this paper
• Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE)

  2018cites this paper
• Effects of repeated dizocilpine treatment on glutamatergic activity in the prefrontal cortex in an animal model of schizophrenia: An in vivo proton magnetic resonance spectroscopy study at 9.4T.

  2017cites this paper
• Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.

  2017cites this paper
• Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis

  2017cites this paper
• Theranostic Biomarkers for Schizophrenia

  2017cites this paper
• In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.

  2017cites this paper
• [Comparative study of glutamate dehydrogenase in the brain of patients with schizophrenia and mentally healthy people].

  2017cites this paper
• Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.

  2016cites this paper
• Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.

  2016cites this paper
• Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample

  2016cites this paper
• Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.

  2016cites this paper
• Neurodevelopmental Theories of Schizophrenia: Twenty‐First Century Perspectives

  2016cites this paper
• Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction

  2016cites this paper
• Measuring Brain Serine With Proton Magnetic Resonance Spectroscopy At 3.0 Tesla

  2016cites this paper
• [Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis].

  2016cites this paper
• Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls

  2015cites this paper
• 1 Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia – A Systematic Review and Meta-Analysis

  2015cites this paper
• Investigation of the neuronal marker N-acetylaspartate as a potential biomarker for neurological diseases

  2015cites this paper
• Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.

  2015cites this paper
• Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy

  2015cites this paper
• Glutamate and dopamine in schizophrenia: An update for the 21st century

  2015cites this paper
• Effect of l-theanine on glutamatergic function in patients with schizophrenia

  2015cites this paper
• Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex

  2015cites this paper
• The Neurodevelopmental Model of Schizophrenia: Updated

  2015cites this paper
• Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. 1H-NMR Spectroscopy Study

  2015cites this paper
• Nuclear Magnetic Resonance Spectroscopy in the Diagnosis of Autism-Related Disorders

  2015cites this paper
• Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients.

  2015influential citation
• Astroglia and Severe Mental Illness: A Role for Glutamate Microdomains

  2014cites this paper
• Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

  2014influential citation
• Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

  2014cites this paper
• Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users

  2014cites this paper
• Glutamatergic metabolite correlations with neuropsychological tests in first episode schizophrenia.

  2014cites this paper
• NMDA pathology and treatment of schizophrenia.

  2014cites this paper
• N-Methyl D-Aspartate Receptor Antagonists Amplify Network Baseline Gamma Frequency (30–80 Hz) Oscillations: Noise and Signal

  2014cites this paper
• Magnetic Resonance Imaging in Studying Schizophrenia, Negative Symptoms, and the Glutamate System

  2014cites this paper
• Disturbed cingulate glutamate metabolism in adults with high-functioning autism spectrum disorder: evidence in support of the excitatory/inhibitory imbalance hypothesis

  2014cites this paper
• The neurobiology and treatment of first-episode schizophrenia

  2014cites this paper
• Glutamate-mediated excitotoxicity in schizophrenia: a review.

  2014cites this paper
• Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.

  2014cites this paper
• Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

  2014cites this paper
• Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis

  2013cites this paper
• T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

  2013cites this paper
• Deregulation of glutamate dehydrogenase in human neurologic disorders

  2013cites this paper
• In the spotlight: Biomedical imaging.

  2013cites this paper
• Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia

  2013cites this paper
• Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia

  2013cites this paper
• Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

  2013cites this paper
• Proton magnetic resonance spectroscopy changes after antipsychotic treatment.

  2013cites this paper
• Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.

  2013cites this paper
• Two‐dimensional J‐resolved proton MR spectroscopy and prior knowledge fitting (ProFit) in the frontal and parietal lobes of healthy volunteers: Assessment of metabolite discrimination and general reproducibility

  2013cites this paper
• Medial Prefrontal Cortex Neurochemical Metabolites in Schizophrenia and Schizoaffective Disorder: A Proton Magnetic Resonance Spectroscopy Study

  2013cites this paper
• The Effect of Insulin Infusion on the Metabolites in Cerebral Tissues Assessed With Proton Magnetic Resonance Spectroscopy in Young Healthy Subjects With High and Low Insulin Sensitivity

  2013cites this paper
• Mesocorticolimbic abnormalities in schizophrenia: A magnetic resonance spectroscopy and diffusion tensor imaging study

  2013cites this paper
• Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

  2012cites this paper
• Clinical and cognitive correlates of the proton magnetic resonance spectroscopy measures in chronic schizophrenia

  2012cites this paper
• Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation

  2012cites this paper
• A framework for interpreting functional networks in schizophrenia

  2012cites this paper
• UvA-DARE ( Digital Academic Repository ) Proton magnetic resonance spectroscopy in 22 q 11 deletion syndrome

  2012cites this paper
• Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

  2012cites this paper
• Update on the neurobiology of schizophrenia: a role for extracellular microdomains.

  2012cites this paper
• A 1H-MRS and Neurocognitive Analysis of Psychotic Symptoms in Stimulant Dependence

  2012cites this paper
• Reliable biomarkers and predictors of schizophrenia and its treatment.

  2012cites this paper